Company intelligence / Profile preview

Biolinq

San Diego, California, United Statesbiolinq.com ↗

Ownership: Private
Development stage: Preclinical

Overview

Biolinq has developed a first-in-class, wearable intradermal glucose sensor patch designed for people with Type 2 diabetes not using insulin. The device provides real-time feedback via a color-changing indicator and combines glucose monitoring with activity/sleep data. The pivotal US clinical trial is complete, and the company is preparing for regulatory submission. No commercial sales or published pivotal results yet.

Therapeutic areas: Endocrinology
Modalities: DeviceWearable biosensorElectrochemical sensor
Industry: Metabolite Diagnostics

Partnerships

Alpha Wave Ventures (lead investor/partner)J.P. Morgan (placement agent for financing)Taisho Pharmaceutical (investor/strategic partner)

Beyond the preview

Go deeper on Biolinq.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Biolinq.

Explore the full profile